Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insight Molecular DiagnosticsIMDX +0.81%49 3-Year EPS without NRI Growth Rate is 44.70% as of Jun. 2026, which is 287% above its 10-year median of 11.55. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 79.75% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 44.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 36.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 19.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Insight Molecular Diagnostics was 44.70% per year. The lowest was -1.30% per year. And the median was 11.55% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Insight Molecular Diagnostics 3-Year EPS without NRI Growth Rate Related Terms
IMDX vs XGN, BNR, BDSX: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's 3-Year EPS without NRI Growth Rate falls into.
Insight Molecular Diagnostics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 44.70% mean?
Insight Molecular Diagnostics (IMDX) has a 3-Year EPS without NRI Growth Rate of 44.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Insight Molecular Diagnostics and its competitors. This is 287% above median its historical median of 11.55. According to the industry distribution chart, Insight Molecular Diagnostics ranks #32 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 20.3%.
Is Insight Molecular Diagnostics' 3-Year EPS without NRI Growth Rate too high?
Insight Molecular Diagnostics' current 3-Year EPS without NRI Growth Rate of 44.70% is 287% above median its 10-year median of 11.55. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.75. Insight Molecular Diagnostics' value of 44.70% is 315.8% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #32 out of 158 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' 3-Year EPS without NRI Growth Rate compare to XGN and BNR?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #32 out of 158 companies for 3-Year EPS without NRI Growth Rate. This places Insight Molecular Diagnostics in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 10.75. Insight Molecular Diagnostics' value of 44.70% is 315.8% above this benchmark. While the company's 10-year median is 11.55 vs. the industry median of 10.75, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current 3-Year EPS without NRI Growth Rate of 44.70% is 315.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current 3-Year EPS without NRI Growth Rate is 44.70%, which is 287% above median its own 10-year median of 11.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.08, compared to a current price of $4.33 — trading 300.9% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 44.70%, which is 287% above median its 10-year median of 11.55 and 315.8% above the Medical Diagnostics & Research industry median of 10.75. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current 3-Year EPS without NRI Growth Rate is 44.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.33 is trading 300.9% above its estimated GF Value™ of $1.08.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
3-Year EPS without NRI Growth Rate: 44.70% (287% above median its 10-year median of 11.55)
GF Value™: $1.08 vs. price of $4.33 (300.9% above fair value)
Industry Position: 315.8% above the Medical Diagnostics & Research median (#32 of 158)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
